Core Viewpoint - Zhuhai Tainuo Maibo Pharmaceutical Co., Ltd. has been accepted for IPO on the Sci-Tech Innovation Board, marking it as the first company to be accepted under the reactivated fifth set of listing standards [3] Company Overview - Tainuo Maibo, established in 2015, focuses on innovative biopharmaceuticals for blood product replacement therapies targeting global markets [3] - The company has developed several candidate antibody drugs, including the globally first-in-class Staitouta monoclonal antibody injection, which has been approved for market [3] - Other candidates include TNM001 (anti-respiratory syncytial virus monoclonal antibody) in Phase III clinical trials, and TNM009 and TNM005 (anti-nerve growth factor and anti-varicella-zoster virus monoclonal antibodies) which have completed Phase I trials [3] Financial Performance - The company reported revenues of 4.34 million yuan in 2022, 0 yuan in 2023, and 1.51 million yuan in 2024, with a revenue of 16,930 yuan in Q1 2025 following the approval of Staitouta [4] - Net losses were reported at 429 million yuan in 2022, 446 million yuan in 2023, 515 million yuan in 2024, and 177 million yuan in Q1 2025 [4] Key Financial Metrics - As of March 31, 2025, total assets amounted to 1.13 billion yuan, with equity attributable to shareholders at 493 million yuan [5] - The company's debt-to-equity ratio was 56.48% as of Q1 2025, indicating a moderate level of financial leverage [5] - The basic and diluted earnings per share were both -0.48 yuan in Q1 2025, reflecting ongoing losses [5] Management and Ownership - The actual controllers, Huaxin Liao and Zheng Weihong, collectively hold 33.10% of the company's shares [5] - Huaxin Liao, the Chairman and CTO, has a background in biochemistry and extensive experience in molecular immunology [6] - Zheng Weihong, the Vice Chairman and General Manager, has a background in business management and experience in the pharmaceutical industry [7] Compensation - In 2024, Huaxin Liao received a salary of 2.63 million yuan, while Zheng Weihong earned 2.61 million yuan, both lower than the salary of the Chief Medical Officer, Wang Guomei, who earned 3.79 million yuan [8][9]

7月31日，上交所网站显示，该所受理了珠海泰诺麦博制药股份有限公司（以下简称"泰诺麦博"）的科创板IPO申请。 图片来源：上交所网站 招股说明书显示，泰诺麦博拟以第五套上市标准申报科创板，公司成为重启科创板第五套上市标准后首家受理的企业。同时，泰诺麦博获得资深专业机构 投资者投资。 泰诺麦博已开发多款抗体药物及候选抗体药物。其中，全球同类首创的斯泰度塔单抗注射液已获批上市，TNM001（抗呼吸道合胞病毒RSV单抗）正在进 行临床III期试验，2款候选药物TNM009（抗神经生长因子NGF单抗）及TNM005（抗水痘-带状疱疹病毒VZV单抗）已完成临床I期试验，1款候选药物 TNM006（抗人巨细胞病毒HCMV单抗）已获批IND，3款候选药物处于临床前阶段。 泰诺麦博表示，上述产品中，斯泰度塔单抗注射液、TNM005为全球同类首创（First-in-Class）或具有全球同类首创潜力，TNM001及TNM006等2款候选 药物具有国产首款潜力。 2022年至2024年，公司研发投入超过11亿元。本次IPO公司拟募资15亿元，募集资金规划用于新药研发项目、抗体生产基地扩建项目和补充营运资金项 目。 本次泰诺麦博获 ...